Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 20/20 | 0.81 |
| ▸ | HTR1B | P28222 | 20/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.81 |
| ▸ | ADRA1B | P35368 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719467 | 0.95 | HTR1A (0.73) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL7720230 | 0.94 | HTR1A (0.72) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6997238 | 0.90 | HTR1A (1.00) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6994225 | 0.87 | HTR1A (0.63) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL7719545 | 0.85 | HTR1A (0.80) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6994812 | 0.85 | HTR1A (0.90) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7719577 | 0.85 | HTR1A (0.60) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7000114 | 0.84 | HTR1A (0.61) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7719473 | 0.83 | HTR1A (0.72) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6995966 | 0.83 | HTR1A (0.72) | HTR1AADRA1DHTR1BADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6387912-B1 | STROKE THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6222034-B1 | AS SEROTININ RECEPTOR ANTAGONISTS; FOR THERAPY OF DEPRESSION, CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-24 | — | — | US | disclosed |